Acute Coronary Syndrome-Pipeline Review, H2 2015

Acute Coronary Syndrome-Pipeline Review, H2 2015

  • Products Id :- GMDHC6819IDB
  • |
  • Pages: 115
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Acute Coronary Syndrome-Pipeline Review, H2 2015


Global Markets Direct's, 'Acute Coronary Syndrome-Pipeline Review, H2 2015', provides an overview of the Acute Coronary Syndrome's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acute Coronary Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Coronary Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Acute Coronary Syndrome

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acute Coronary Syndrome

and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acute Coronary Syndrome

products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acute Coronary Syndrome

pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acute Coronary Syndrome

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acute Coronary Syndrome

pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Acute Coronary Syndrome Overview 9

Therapeutics Development 10

Pipeline Products for Acute Coronary Syndrome-Overview 10

Pipeline Products for Acute Coronary Syndrome-Comparative Analysis 11

Acute Coronary Syndrome-Therapeutics under Development by Companies 12

Acute Coronary Syndrome-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Acute Coronary Syndrome-Products under Development by Companies 17

Acute Coronary Syndrome-Companies Involved in Therapeutics Development 18

advanceCor GmbH 18

Arena Pharmaceuticals, Inc. 19

Artery Therapeutics, Inc. 20

Athera Biotechnologies AB 21

Bayer AG 22

Cardiome Pharma Corp. 23

Cerenis Therapeutics Holding SA 24

Esperion Therapeutics, Inc. 25

GlaxoSmithKline Plc 26

Lee's Pharmaceutical Holdings Limited 27

MedImmune, LLC 28

Pfizer Inc. 29

Teva Pharmaceutical Industries Limited 30

The Medicines Company 31

Vitae Pharmaceuticals, Inc. 32

XOMA Corporation 33

Acute Coronary Syndrome-Therapeutics Assessment 34

Assessment by Monotherapy Products 34

Assessment by Target 35

Assessment by Mechanism of Action 37

Assessment by Route of Administration 39

Assessment by Molecule Type 41

Drug Profiles 43

4-WF-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

AEM-28-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

AEM-28-02-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Artpep-2-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

Biologics for Acute Coronary Syndrome-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

CER-001-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

COR-2-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

COR-3-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

gevokizumab-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

losmapimod-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

MDCO-216-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

MEDI-6012-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

PC-mAb-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

PF-06282999-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

PMC-6-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

PR-15-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

rivaroxaban-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

SD-970-Drug Profile 73

Product Description 73

Mechanism of Action 73

R&D Progress 73

temanogrel hydrochloride-Drug Profile 74

Product Description 74

Mechanism of Action 74

R&D Progress 74

tirofiban hydrochloride-Drug Profile 75

Product Description 75

Mechanism of Action 75

R&D Progress 75

VTP-38443-Drug Profile 76

Product Description 76

Mechanism of Action 76

R&D Progress 76

ZK-001-Drug Profile 77

Product Description 77

Mechanism of Action 77

R&D Progress 77

Acute Coronary Syndrome-Recent Pipeline Updates 79

Acute Coronary Syndrome-Dormant Projects 101

Acute Coronary Syndrome-Dormant Projects 101

Acute Coronary Syndrome-Discontinued Products 103

Acute Coronary Syndrome-Product Development Milestones 105

Featured News & Press Releases 105

May 11, 2015: Xarelto Bleeding Lawsuit Judge Orders the Selection of Cases for Discovery, Reports Xarelto Lawsuit Funding Firm, Fair Rate Funding 105

Apr 23, 2015: Medicure Announces Approval of Expanded Dosing Time For AGGRASTAT 105

Oct 22, 2014: NICE draft guidance recommends rivaroxaban (Xarelto) to prevent blood clots in people who have had a heart attack 106

Sep 02, 2014: Capstone Therapeutics Announces Phase 1a Results for AEM-28 Showing Safety and Biomarker Efficacy Signals 107

Aug 29, 2014: Janssen Expands EXPLORER Global Cardiovascular Research Program to Evaluate the Role of XARELTO in Addressing Critical Medical Needs 107

Jun 05, 2014: GSK announces start of phase III cardiovascular outcomes study with losmapimod in patients with acute coronary syndrome 109

Jan 16, 2014: FDA Advisory Committee Recommends Against Approval of the Use of Oral Anticoagulant XARELTO to Reduce the Risk of Thrombotic Cardiovascular Events in Patients with Acute Coronary Syndrome 110

Jan 02, 2014: Cerenis Reports Top-Line Phase II Results for its HDL Mimetic CER-001 111

Nov 14, 2013: Real-World Data Confirm Clinical Value of Bayer's Novel Oral Anticoagulant Xarelto in Protecting Patients Against Blood Clots 112

Oct 07, 2013: Regulatory Update on Bayer's Xarelto (Rivaroxaban) 2.5 mg in ACS Indication 113

Appendix 114

Methodology 114

Coverage 114

Secondary Research 114

Primary Research 114

Expert Panel Validation 114

Contact Us 114

Disclaimer 115

List of Tables

Number of Products under Development for Acute Coronary Syndrome, H2 2015 10

Number of Products under Development for Acute Coronary Syndrome-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 13

Comparative Analysis by Late Stage Development, H2 2015 14

Comparative Analysis by Clinical Stage Development, H2 2015 15

Comparative Analysis by Early Stage Development, H2 2015 16

Products under Development by Companies, H2 2015 17

Acute Coronary Syndrome-Pipeline by advanceCor GmbH, H2 2015 18

Acute Coronary Syndrome-Pipeline by Arena Pharmaceuticals, Inc., H2 2015 19

Acute Coronary Syndrome-Pipeline by Artery Therapeutics, Inc., H2 2015 20

Acute Coronary Syndrome-Pipeline by Athera Biotechnologies AB, H2 2015 21

Acute Coronary Syndrome-Pipeline by Bayer AG, H2 2015 22

Acute Coronary Syndrome-Pipeline by Cardiome Pharma Corp., H2 2015 23

Acute Coronary Syndrome-Pipeline by Cerenis Therapeutics Holding SA, H2 2015 24

Acute Coronary Syndrome-Pipeline by Esperion Therapeutics, Inc., H2 2015 25

Acute Coronary Syndrome-Pipeline by GlaxoSmithKline Plc, H2 2015 26

Acute Coronary Syndrome-Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015 27

Acute Coronary Syndrome-Pipeline by MedImmune, LLC, H2 2015 28

Acute Coronary Syndrome-Pipeline by Pfizer Inc., H2 2015 29

Acute Coronary Syndrome-Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 30

Acute Coronary Syndrome-Pipeline by The Medicines Company, H2 2015 31

Acute Coronary Syndrome-Pipeline by Vitae Pharmaceuticals, Inc., H2 2015 32

Acute Coronary Syndrome-Pipeline by XOMA Corporation, H2 2015 33

Assessment by Monotherapy Products, H2 2015 34

Number of Products by Stage and Target, H2 2015 36

Number of Products by Stage and Mechanism of Action, H2 2015 38

Number of Products by Stage and Route of Administration, H2 2015 40

Number of Products by Stage and Molecule Type, H2 2015 42

Acute Coronary Syndrome Therapeutics-Recent Pipeline Updates, H2 2015 79

Acute Coronary Syndrome-Dormant Projects, H2 2015 101

Acute Coronary Syndrome-Dormant Projects (Contd..1), H2 2015 102

Acute Coronary Syndrome-Discontinued Products, H2 2015 103

Acute Coronary Syndrome-Discontinued Products (Contd..1), H2 2015 104

List of Figures

Number of Products under Development for Acute Coronary Syndrome, H2 2015 10

Number of Products under Development for Acute Coronary Syndrome-Comparative Analysis, H2 2015 11

Number of Products under Development by Companies, H2 2015 12

Comparative Analysis by Clinical Stage Development, H2 2015 15

Assessment by Monotherapy Products, H2 2015 34

Number of Products by Top 10 Targets, H2 2015 35

Number of Products by Stage and Top 10 Targets, H2 2015 35

Number of Products by Top 10 Mechanism of Actions, H2 2015 37

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 37

Number of Products by Top 10 Routes of Administration, H2 2015 39

Number of Products by Stage and Top 10 Routes of Administration, H2 2015 39

Number of Products by Top 10 Molecule Types, H2 2015 41

Number of Products by Stage and Top 10 Molecule Types, H2 2015 41

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

advanceCor GmbH

Arena Pharmaceuticals, Inc.

Artery Therapeutics, Inc.

Athera Biotechnologies AB

Bayer AG

Cardiome Pharma Corp.

Cerenis Therapeutics Holding SA

Esperion Therapeutics, Inc.

GlaxoSmithKline Plc

Lee's Pharmaceutical Holdings Limited

MedImmune, LLC

Pfizer Inc.

Teva Pharmaceutical Industries Limited

The Medicines Company

Vitae Pharmaceuticals, Inc.

XOMA Corporation

Acute Coronary Syndrome Therapeutic Products under Development, Key Players in Acute Coronary Syndrome Therapeutics, Acute Coronary Syndrome Pipeline Overview, Acute Coronary Syndrome Pipeline, Acute Coronary Syndrome Pipeline Assessment

select a license

Single User License
USD 2000 INR 136600
Site License
USD 4000 INR 273200
Corporate User License
USD 6000 INR 409800



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]